PORT HUENEME, CA--(Marketwire - December 14, 2010) - Stellar Biotechnologies, Inc. (
John Sundsmo, Ph. D., Stellar's VP, Research & IP Management, commented, "This grant expands the scope of our 2009 $470,000 award to include critical research that will enhance Stellar's commercial partnerships. The research advances IP for Stellar, and puts us in excellent position for more significant grants to advance the commercial development of this important scientific work, while creating a sustainable supply of the sole KLH source, the keyhole limpet."
Stellar also announces an interview with CEO, Frank Oakes, and Executive VP, Darrell Brookstein: http://www.pinnacledigest.com/podcast/interview-stellar-biotechnologies-ceo-and-vp-big-pharma-interest-little-market-cap-company
Stellar Biotechnologies, Inc. (
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.
Contact Information:
Contact:
Darrell Brookstein
dbrookstein@stellarbiotech.com